Newswise — Comprehensive guidelines for the treatment and management of hypertension in children and adolescents are being published for the first time in the latest issue of the Journal of Hypertension. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Prepared by a Task Force established by the European Society of Hypertension, the guidelines will prove to be an invaluable source of information for physicians, nurses and families dealing with hypertension in young people.
The necessity for the guidelines has become increasingly clear to physicians in light of growing evidence that cases of mild hypertension in children and adolescents are much more common than previously thought. In addition, progress made in pathophysiological and clinical research has made clear links between paediatric hypertension and cardiovascular disease later in life, highlighting the need for improved cardiovascular prevention strategies for pre-adult individuals.
The Task Force, set up by the European Society of Hypertension and headed by Dr Empar Lurbe of the University of Valencia, has combined considerable amounts of scientific data with clinical experience in order to represent a consensus among specialists involved in the detection and control of high blood pressure (BP) in children and adolescents. It is hoped that the publication of these guidelines will call attention to the burden of hypertension in children and adolescents, and encourage public policy makers to develop a global effort to improve identification and treatment of high BP among young people. Primarily, however, these guidelines provide practical strategies for diagnosing and treating hypertension in children and adolescents. They include:
* Definition and classification of hypertension
* Diagnostic evaluation
* Preventative measures
* Evidence for therapeutic management
* Therapeutic strategies and approaches under special conditions
* Treatment of associated risk factors
* Screening for secondary forms of hypertension
The Task Force also suggests strategies for long term follow up, and make recommendations for future research in the field.
The guidelines will certainly prove vital in combating the growing epidemic of cardiovascular disease in adults, by emphasising the need for preventative strategies to be implemented from an early age. As Dr Lurbe comments, "Action is required to address this problem in one of the most vulnerable and precious sectors of our society: children and adolescents."
About The Journal of Hypertension
The journal consistently attracts the most important and highly innovative papers from the current research; our commitment to rapid publication ensures that these are published in the fastest time possible. In addition to primary papers from world-renowned experts, the Journal contains authoritative reviews that summarize and evaluate the most significant recent developments. Also included are special reports, original short papers containing innovative and time-sensitive information.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
RSS